searnshawrti.org
919-485-2730
Research Triangle Park, NC

Stephanie R. Earnshaw

Expertise

Health Economics
Pharmacoeconomics
Operations Research

Biography

Stephanie Earnshaw, PhD, is a research management scientist at RTI Health Solutions. Dr. Earnshaw applies mathematical modeling, optimization, and decision analysis techniques to industry-related issues and health care problems. She has also extensive experience in survey management. Her areas of specialization include systems optimization and solving resource allocation problems. She has developed innovative mathematical models to determine pricing strategy, budget impact, and cost-effectiveness of new products. Dr. Earnshaw has developed a variety of mathematical models, including Markov models, Monte Carlo simulation models, and other state transition models, to analyse the impact of new medical interventions on disease progression. Dr. Earnshaw also has extensive programming experience and has led programmers in developing user interfaces for health surveys and for several pharmacoeconomic models. Dr. Earnshaw is a member of the Institute for Operations Research and the Management Sciences. She has presented her work at professional conferences and has published in several peer-reviewed journals.

Education

PhD, Industrial Engineering (Operations Research and Management), North Carolina State University; MS, Industrial Engineering (Operations Research), North Carolina State University; BS, Mathematical Science (Operations Research), University of North Carolina at Chapel Hill.

Selected Publications

Bell, C., Graham, J.B., Earnshaw, S., Oleen-Burkey, M.K., Castelli-Haley, J., & Johnson, K. (April 2007). Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Journal of Managed Care Pharmacy, 13 (3):245-261.

Pignone, M., Earnshaw, S., Pletcher, M.J., & Tice, J.A. (February 12, 2007). Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Archives of Internal Medicine, 167 (3):290-295.

Earnshaw, S.R., & Wilson, M. (January 2007). The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface, 19 (11):39-45.

Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., & Sabatowski, R. (December 2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. European Journal of Health Economics, 7 (4):290-296.

Earnshaw, S.R., Joshi, A.V., Wilson, M.R., & Rosand, J. (Nov 2006). Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke, 37 (11):2751-2758.

Pignone, M., Earnshaw, S., Tice, J.A., & Pletcher, M.J. (2006 Mar 7). Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Annals of Internal Medicine, 144 (5):326-336.

Earnshaw, S.R., Candrilli, S.D., Fernandes, A.W., & Higashi, M.K. (2005). A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface, 18 (10):36-44.

Mauskopf, J.A., Earnshaw, S.R., & Mullins, C. (May 2005). Budget impact analysis: review of the state of the art. Expert Review of Pharmacoeconomics & Outcomes Research, 5 (1):65-79.

Earnshaw, S.R., & Dennett, S.L. (2003). Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics, 21 (12):839-851.

Earnshaw, S.R., Richter, A., Sorensen, S.W., Hoerger, T.J., Hicks, K.A., Engelgau, M., Thompson, T., Narayan, K.M.V., Williamson, D.E., Gregg, E., & Zhang, P. (2002). Optimal allocation of resources across four interventions for type 2 diabetes. Medical Decision Making, 22 (5):S80-S91.

View all publications by Stephanie R. Earnshaw…